Kate Godfrey
Research Associate at Imperial College London’s Centre for Psychedelic Research
Data updated
Research Footprint
Kate Godfrey appears in 8 tracked papers (2023–2026), most studied alongside Psilocybin, LSD and Ketamine, across Neuroimaging & Brain Measures, Healthy Volunteers and Microdosing.
Most-cited paper: Acute mood-elevating properties of microdosed LSD in healthy volunteers: a home-administered randomised controlled trial (67 citations).
Frequent co-authors: Robin Carhart-Harris, David Erritzoe and David Nutt.
Background & Research
Kate Godfrey completed her PhD in pharmacy at the University of Auckland, where she studied neurological correlates of antidepressant response to brain stimulation treatment. She later moved to Imperial College London’s Centre for Psychedelic Research, where she has worked on EEG and other studies of psychedelics, including microdosed LSD and psilocybin-related research. Her work focuses on the neurobiological mechanisms and potential therapeutic applications of psychedelics, especially measures of neuroplasticity.
Key Impact
Kate Godfrey is notable for contributing to leading human psychedelic research on microdosing, neuroimaging, and neuroplasticity at Imperial College London.
Collaboration Network
27 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Kate Godfrey is associated with.